Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 8/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | MAOA | P21397 | 5/20 | 0.57 |
| ▸ | LCK | P06239 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 6/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.57 |
| ▸ | BLM | P54132 | 2/20 | 0.57 |
| ▸ | PTPRC | P08575 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18984783 | 0.85 | ALDH1A1 (0.72) | ALDH1A1TDP1MAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL21635983 | 0.84 | ALDH1A1 (0.65) | ALDH1A1TDP1MAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL6661622 | 0.84 | ALDH1A1 (0.65) | ALDH1A1TDP1MAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL27907642 | 0.83 | ALDH1A1 (0.69) | ALDH1A1TDP1MAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL30614481 | 0.80 | LCK (0.67) | ALDH1A1TDP1MAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL27907616 | 0.80 | LCK (0.67) | ALDH1A1TDP1MAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL3135129 | 0.80 | NPC1 (0.86) | ALDH1A1TDP1MAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL516210 | 0.80 | NPC1 (0.86) | ALDH1A1TDP1MAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL6906327 | 0.79 | TTR (0.72) | ALDH1A1TDP1MAPK1CYP3A4SMN1; SMN2 | |
| SCHEMBL28005394 | 0.78 | NPC1 (0.82) | ALDH1A1TDP1MAPK1CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087935-B1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INT LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20030203975-A1 | Anti-cancer agents | BTG INTERNATIONAL LIMITED (GB) | 2003-10-30 | — | — | US | disclosed |
| US-20030130272-A1 | Anthracene derivatives as anti-cancer agents | BTG INTERNATIONAL LIMITED (GB) | 2003-07-10 | — | — | US | disclosed |
| EP-1087935-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065866-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130272-A1 | Anthracene derivatives as anti-cancer agents | TOP2B, TOP1, TOP2A | ALDH1A1 3026/4885TDP1 714/4885MAPK1 3848/4885 |
| US-20030203975-A1 | Anti-cancer agents | TOP2B, TOP2A, TOP1 | ALDH1A1 3625/4885TDP1 1180/4885MAPK1 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.